Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Long-Term Follow-Up of Subjects in a Phase 1, 2, or 3 Clinical Trial in Which Boceprevir or Narlaprevir Was Administered for the Treatment of Chronic Hepatitis C

NCT00689390 is registered in ClinicalTrials.gov with Merck Sharp & Dohme LLC as lead sponsor.

NCT NCT00689390
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00689390 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Long-Term Follow-Up of Subjects in a Phase 1, 2, or 3 Clinical Trial in Which Boceprevir or Narlaprevir Was Administered for the Treatment of Chronic Hepatitis C
Lead sponsor
Merck Sharp & Dohme LLC
Phase
Phase 2/3
Overall status
Terminated
Start date
February 20, 2007
Completion date
October 13, 2014
Enrollment
1,954 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

hepacivirus, hepatitis c, chronic